Clinical Report: Prognostic Significance of Lipoprotein(a) and Inflammatory-Lipid Index

Overview

This study evaluates the prognostic value of lipoprotein(a) and a novel Inflammatory-Lipid Index in patients with acute coronary syndrome and type 2 diabetes mellitus.

Background

Acute coronary syndrome (ACS) significantly contributes to cardiovascular mortality, particularly in patients with type 2 diabetes mellitus (T2DM), who face a higher risk of recurrent major adverse cardiovascular events (MACE). Despite advancements in lipid-lowering therapies, residual cardiovascular risk persists, necessitating the identification of non-traditional biomarkers.

Data Highlights

Key Findings

• Lipoprotein(a) and the Inflammatory-Lipid Index are independent predictors of MACE in ACS patients with T2DM.
• Patients with high levels of both biomarkers had an 8-fold higher risk of MACE compared to those with low levels.
• Non-linear correlations were observed between both biomarkers and MACE risk.
• The dual-biomarker approach identifies a high-risk phenotype among ACS patients with T2DM.

Clinical Implications

The findings suggest that measuring lipoprotein(a) and the Inflammatory-Lipid Index can enhance cardiovascular risk assessment in ACS patients with T2DM. This dual approach may guide more tailored secondary prevention strategies for high-risk individuals.

Conclusion

The concomitant elevation of lipoprotein(a) and the Inflammatory-Lipid Index provides valuable prognostic information, identifying patients at particularly high risk for adverse cardiovascular events.

Related Resources & Content

1. Frontiers in Endocrinology, 2026 -- Atherogenic index of plasma and the severity of coronary artery stenosis in patients with type 2 diabetes mellitus: a retrospective cross-sectional study
2. European Journal of Preventive Cardiology, 2023 -- Association of Conventional Risk Factors, Ideal Cardiovascular Health, and Increased Lipoprotein(a) Levels
3. ACC/AHA Issue Updated Guideline for Managing Lipids, Cholesterol, 2026
4. Frontiers in Endocrinology — Quantifying the metabolic-inflammatory axis: synergistic value of TyG index and FAI in assessing CAD risk among MAFLD patients
5. European Journal of Preventive Cardiology — The Risk of Atherosclerotic Cardiovascular Disease Linked to Lipoprotein(a) Remains Unaffected by C-Reactive Protein Levels
6. 2025 ESC/EAS Dyslipidaemia Focused Update
7. ACC/AHA Issue Updated Guideline for Managing Lipids, Cholesterol - American College of Cardiology
8. Prognostic value of elevated lipoprotein (a) in patients with acute coronary syndromes: a systematic review and meta-analysis - PMC
9. PROGNOSTIC VALUE OF HIGH-SENSITIVITY C-REACTIVE PROTEIN (HS-CRP) IN PREDICTING FUTURE CARDIOVASCULAR EVENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS - ScienceDirect
10. Full article: High apoB/apoA-1 ratio is a strong risk predictor of major adverse cardio- and cerebrovascular events part 1: a review basis for updating guidelines
11. Content Click below to navigate through the docu
12. Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a) - ScienceDirect
13. Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a) | New England Journal of Medicine